Rapid detection of metastatic thyroid cancer using a point of care assay
Official title: Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma- A Multi-Center Validation Study
Run by Soroka University Medical Center · NCT05078853 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new quick test for thyroid cancer to see if it works better than the usual methods for patients who might have advanced thyroid cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 120 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Soroka University Medical Center Academic / other |
| Locations | 5 sites (Ashkelon and 4 other locations) |
| Trial ID | NCT05078853 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with suspected or known differentiated thyroid carcinoma and associated cervical lymph node metastases.
✕Probably not a fit
Patients who are pregnant or do not consent to participate will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to validate a novel point of care assay for thyroglobulin (POC-Tg) in patients with suspected metastatic differentiated thyroid carcinoma (DTC). The study will assess the accuracy of POC-Tg compared to traditional diagnostic methods in both a fine needle aspiration clinic and during surgical procedures. By providing immediate results, the POC-Tg could significantly reduce the waiting time for patients and improve treatment planning. The study will be conducted across multiple centers, with data managed centrally for comprehensive analysis.
Why it matters
Potential benefit: If successful, this approach could lead to faster diagnosis and treatment decisions for patients with metastatic differentiated thyroid carcinoma.
How similar studies have gone: While similar diagnostic approaches have been explored, the specific use of a point of care assay for thyroglobulin in this context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Patients who are able and agree to sign the informed consent document.
2. Aged 18 years or older.
In the FNA clinic arm:
3. Patients evaluated for thyroid nodule/s suspected or known as DTC, accompanied by cervical LN/s suspected as DTC metastasis.
4. Patients following treatment for DTC (partial or total thyroidectomy, with or without compartmental neck dissection), with cervical LN/s suspected as DTC recurrency.
In the OR arm:
5. Patients operated for known DTC (partial or total thyroidectomy, with or without compartmental neck dissection).
6. Patients operated for DTC recurrency ('completion' and/or compartmental neck dissection).
-
Exclusion Criteria:
Pregnant women
-
Where it's running
-
Barzilai Medical Center
Ashkelon, Israel Recruiting -
Soroka University Medical Center
Beer Sheva, Israel Recruiting -
Hebrew University Medical Center, Mount Scopus
Jerusalem, Israel Recruiting -
Sheba Medical Center
Ramat Gan, Israel Recruiting -
A.R.M Medical Center, Assuta Ramat Hahayal
Tel Aviv, Israel Recruiting
Study contacts
- Principal investigator: Uri Yoel, M.D. — Soroka University Medical Center, Beer Sheva, Israel
- Study coordinator: Uri Yoel, M.D.
- Email: uriy@bgu.ac.il
- Phone: +972548184277
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized drug combos for advanced thyroid cancer
This phase Ib study tests whether customized drug combinations, chosen from existing approved medicines based on a patient’s tumor genetics, can be safely given to people with advanced thyroid cancer when standard options are limited.
-
F-18 Tetrafluoroborate PET/CT to find recurrent or residual differentiated thyroid cancer
This test will see if F-18 Tetrafluoroborate PET/CT finds recurrent or residual differentiated thyroid cancer better than standard F-18 FDG PET/CT in adults who had surgery and radioactive iodine and now have rising thyroglobulin or anti-thyroglobulin.
-
Predicting challenges in thyroid surgery
This study is trying to find out which factors can help doctors predict how challenging thyroid surgery will be for patients with thyroid cancer so they can plan better and keep patients safe.
-
Treatment for RET Fusion Thyroid Cancer in Young Patients
This study is testing a new treatment combining selpercatinib and radioactive iodine for children and young adults with a specific type of thyroid cancer to see if it helps improve their condition after surgery.
-
Evaluating NRT6008 for patients with advanced pancreatic cancer
This study is testing a new injection called NRT6008 to see if it is safe and effective for people with advanced pancreatic cancer that can't be removed by surgery.
-
Treatment for advanced thyroid cancers using sacituzumab govitEcan
This study is testing a new drug called sacituzumab govitEcan to see if it can help people with advanced thyroid cancers that don't respond to traditional treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.